Application of the modified vaccination technique for the prevention and cure of chronic ailments

Asian Pacific Journal of Tropical Medicine

Volumn 3, Issue 2, 2010, Pages 160-166

  Barabas, Arpad Z ^a   Cole, Chad D ^b   Barabas, Arpad D ^a   Graeff, Richard M ^c   Lafreniere, Rene ^a   Weir, Donald M ^d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Autoimmunity; Modified vaccination technique; Prophylactic; Therapeutic

Indexed keywords

ALCOHOL; CANCER VACCINE; DIPHTHERIA VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; KIDNEY ANTIGEN; KIDNEY FRACTION 3 ANTIGEN; TETANUS TOXOID; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER CELL; CELL KILLING; DIPHTHERIA; DRUG SAFETY; HEALTH PROGRAM; HEYMANN NEPHRITIS; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; NONHUMAN; PASSIVE IMMUNIZATION; PROPHYLAXIS; TETANUS; TUMOR IMMUNOLOGY; VACCINATION;

EID: 77950680450     PISSN: 19957645     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1995-7645(10)60060-0     Document Type: Article

References (101)

1. Barabas AZ, Cole CD, Barabas AD, Lafreniere R Down-regulation of pathogenic autoantibody response in a slowly progressive Heymann nephritis kidney disease model. Int J Exp Pathol 2004, 85(6):321-334.
2. Barabas AZ, Lafreniere R Antigen-specific down-regulation of immunopathological events in an experimental autoimmune kidney disease. Autoimmun Rev 2005, 4(8):565-570.
3. Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R Reduced incidence of slowly progressive Heymann nephritis in rats immunized with a modified vaccination technique. Clin Dev Immunol 2006, 13(1):17-24.
4. Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R A vaccination technique to combat presently untreatable chronic ailments. Bio Processing Journal 2007, 6(4):12-18.
5. Barabas AZ, Cole CD, Barabas AD, Lafreniere R Preventative and therapeutic vaccination to combat an experimental autoimmune kidney disease. Biologics: Targets & Therapy 2007, 1(1):59-68.
6. Barabas AZ, Cole CD, Barabas AD, Lafreniere R A modified vaccination technique for the prevention and treatment of an experimental autoimmune kidney disease. Ann N Y Acad Sci 2007, 1110:619-629.
7. Barabas AZ, Cole CD, Barabas AD, Bahlis NJ, Lafreniere R New vaccination technology for endogenous antigen-derived ailments. IDrugs 2008, 11(2):111-115.
8. Barabas AZ, Weir DM, Cole CD, Barabas AD, Bahlis NJ, Graeff RM, et al. Preventing and treating chronic disorders using the modified vaccination technique. Front Biosci 2009, 14:3892-3898.
9. Barabas AZ, Cole CD, Barabas AD, Lafreniere R Downregulation of a pathogenic autoantibody response by IgM autoantibodies directed against the nephritogenic antigen in slowly progressive Heymann nephritis. Pathol Int 2006, 56(4):181-190.
10. Alballa S, Fritzler M, Davis P A case of drug induced lupus due to carbamazepine. J Rheumatol 1987, 14(3):599-600.
11. Barabas AZ, Cole CD, Barabas AD, Lafreniere R Production of Heymann nephritis by a chemically modified renal antigen. Int J Exp Pathol 2004, 85(5):277-285.
12. Jiang X, Khursigara G, Rubin RL Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994, 266(5186):810-813.
13. Totoritis MC, Rubin RL Drug-induced lupus. Genetic, clinical, and laboratory features. Postgrad Med 1985, 78(3):149-161.
14. Yung R, Powers D, Johnson K, Amento E, Carr D, Laing T, et al. Mechanisms of drug-induced lupus. II. T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic mice. J Clin Invest 1996, 97(12):2866-2871.
15. Heymann W, Hackel DB, Harwood S, Wilson SG, Hunter JLP Production of the nephritic syndrome in rat by Freund's adjuvant and rat kidney suspension. Proc Soc Exp Biol Med 1959, 100:660-664.
16. Barabas AZ, Cole CD, Barabas AD, Graeff RM, Lafreniere R, Weir DM Correcting autoimmune anomalies in autoimmune disorders by immunological means, employing the modified vaccination technique. Autoimmun Rev 2009, 8(7):552-557.
17. Avrameas S Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today 1991, 12(5):154-159.
18. Weir DM, Pinckard RN, Elson CJ, Suckling DE Naturally occurring anti-tissue antibodies in rat sera. Clin Exp Immunol 1966, 1(4):433-442.
19. + B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today 1989, 10(11):364-368.
20. Weir DM Immunological reaction after tissue injury. Lancet 1964, 1:749-750.
21. Weir DM The immune response after tissue injury. Pathol Eur 1966, 1(1):108-118.
22. Batsford SR, Weghaupt R, Takamiya H, Vogt A Studies on the mesangial handling of protein antigens: influence of size, charge and biologic activity. Nephron 1985, 41(2):146-151.
23. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci USA 2000, 97(3):1184-1189.
24. Condemi JJ SLE: idiopathic or drug-induced?. Geriatrics 1980, 35(3):81-88.
25. Rich MW Drug-induced lupus. The list of culprits grows. Postgrad Med 1996, 100(3):299-308.
26. Weir DM, Pinckard RN Failure to induce tolerance to rat tissue antigens. Immunology 1967, 13(4):373-380.
27. Weir DM, Elson CJ Antitissue antibodies and immunological tolerance to self. Arthritis Rheum 1969, 12(3):254-260.
28. Barabas AZ, Cole CD, Barabas AD, Lafreniere R Production of a new model of slowly progressive Heymann nephritis. Int J Exp Pathol 2003, 84(6):245-258.
29. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349(16):1526-1533.
30. Berinstein NL Enhancing cancer vaccines with immunomodulators. Vaccine 2007, 25(2):B72-B88.
31. Lollini PL, Forni G Antitumor vaccines: is it possible to prevent a tumor?. Cancer Immunol Immunother 2002, 51(8):409-416.
32. Milstein C, Waldmann H Optimism after much pessimism: what next?. Curr Opin Immunol 1999, 11(5):589-591.
33. Petrovsky N, Aguilar JC Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(5):488-496.
34. Albert LJ, Inman RD Molecular mimicry and autoimmunity. N Engl J Med 1999, 341(27):2068-2074.
35. Ebringer A, Thorpe C, Pirt J, Wilson C, Cunningham P, Ettelaie C Bovine spongiform encephalopathy: is it an autoimmune disease due to bacteria showing molecular mimicry with brain antigens?. Environ Health Perspect 1997, 105(11):1172-1174.
36. Ebringer A Molecular mimicry as the basis of a new theory of autoimmunity. Frontiers in Autoimmunity: fundamental aspects and clinical perspectives 2003, 79-99. IOS Press, Netherlands. M. Zouali (Ed.).
37. Ban Y, Tomer Y Susceptibility genes in thyroid autoimmunity. Clin Dev Immunol 2005, 12(1):47-58.
38. Conti F, Rezai S, Valesini G Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008, 8(2):124-128.
39. Davidson A, Diamond B Autoimmune diseases. N Engl J Med 2001, 345(5):340-350.
40. Molina V, Shoenfeld Y Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005, 38(3):235-245.
41. Morahan G, Morel L Genetics of autoimmune diseases in humans and in animal models. Curr Opin Immunol 2002, 14(6):803-811.
42. Pramatarov KD Drug-induced lupus erythematosus. Clin Dermatol 1998, 16(3):367-377.
43. Price EJ, Venables PJ Drug-induced lupus. Drug Saf 1995, 12(4):283-290.
44. Ramsey-Goldman R, Franz T, Solano FX, Medsger TA Hydralazine induced lupus and Sweet's syndrome. Report and review of the literature. J Rheumatol 1990, 17(5):682-684.
45. Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y, et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases-2008. Isr Med Assoc J 2008, 10(1):8-12.
46. Hess EV Are there environmental forms of systemic autoimmune diseases?. Environ Health Perspect 1999, 107(Suppl 5):709-711.
47. Rao T, Richardson B Environmentally induced autoimmune diseases: potential mechanisms. Environ Health Perspect 1999, 107(Suppl 5):737-742.
48. Andres G, Brentjens JR, Caldwell PR, Camussi G, Matsuo S Formation of immune deposits and disease. Lab Invest 1986, 55(5):510-520.
49. Barabas AZ, Lannigan R Auto-immune nephritis in rats. J Pathol 1969, 97(3):537-543.
50. Barabas AZ, Elson CJ, Weir DM The serology of autologous immune complex nephritis in the rat. Clin Exp Immunol 1969, 4(3):345-351.
51. Grupe WE, Kaplan MH Demonstration of an antibody to proximal tubular antigen in the pathogenesis of experimental autoimmune nephrosis in rats. J Lab Clin Med 1969, 74(3):400-409.
52. Kerjaschki D, Farquhar MG The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci USA 1982, 79(18):5557-5581.
53. Kerjaschki D Molecular development of immune deposits and proteinuria in Heymann nephritis. Clin Investig 1993, 71(10):817-821.
54. Kerjaschki D Pathogenetic concepts of membranous glomerulopathy (MGN). J Nephrol 2000, 13(Suppl 3):S96-100.
55. Kretz-Rommel A, Duncan SR, Rubin RL Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus. J Clin Invest 1997, 99(8):1888-1896.
56. Kretz-Rommel A, Rubin RL Persistence of autoreactive T cell drive is required to elicit anti-chromatin antibodies in a murine model of drug-induced lupus. J Immunol 1999, 162(2):813-820.
57. Sinha AA, Lopez MT, McDevitt HO Autoimmune diseases: the failure of self tolerance. Science 1990, 248(4961):1380-1388.
58. Theofilopoulos AN The basis of autoimmunity: Part I. Mechanisms of aberrant self-recognition. Immunol Today 1995, 16(2):90-98.
59. Tung KS Mechanism of self-tolerance and events leading to autoimmune disease and autoantibody response. Clin Immunol Immunopathol 1994, 73(3):275-282.
60. von Herrath MG, Oldstone MB Role of viruses in the loss of tolerance to self-antigens and in autoimmune diseases. Trends Microbiol 1995, 3(11):424-430.
61. Manz RA, Arce S, Cassese G, Hauser AE, Hiepe F, Radbruch A Humoral immunity and long-lived plasma cells. Curr Opin Immunol 2002, 14(4):517-521.
62. Mokhtarian F, Zhang Z, Shi Y, Gonzales E, Sobel RA Molecular mimicry between a viral peptide and a myelin oligodendrocyte glycoprotein peptide induces autoimmune demyelinating disease in mice. J Neuroimmunol 1999, 95(1-2):43-54.
63. Orbach H, Shoenfeld Y Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 2007, 6(5):261-266.
64. Alas S, Bonavida B Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001, 61(13):5137-5144.
65. Barabas AZ, Nagi AH, Lannigan R, Womersley RA The effect of cortisone treatment on autologous immune complex glomerulonephritis in rats. Br J Exp Pathol 1970, 51(6):541-546.
66. Cope AP, Feldmann M Emerging approaches for the therapy of autoimmune and chronic inflammatory disease. Curr Opin Immunol 2004, 16(6):780-786.
67. Feldmann M, Steinman L Design of effective immunotherapy for human autoimmunity. Nature 2005, 435(7042):612-619.
68. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83(2):435-445.
69. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353(16):1673-1684.
70. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792.
71. Canzler U, Bartsch H, Ulitzsch S, Kurien BT, Dorri Y, Scofield RH, et al. Detection of autoantibodies to tumour-associated antigens in sera of patients with systemic autoimmunity using a novel protein microblot array. Scand J Immunol 2009, 69(6):563-569.
72. Liu Q, Kriksunov IA, Graeff R, Munshi C, Lee HC, Hao Q Crystal structure of human CD38 extracellular domain. Structure 2005, 13(9):1331-1339.
73. Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008, 99(9):1415-1425.
74. Harel M, Shoenfeld Y Predicting and preventing autoimmunity, myth or reality?. Ann N Y Acad Sci 2006, 1069:322-345.
75. Coiffier B Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol 2002, 29(1 Suppl 2):30-35.
76. Czuczman MS, Fallon A, Mohr A, Stewart C, Bernstein ZP, McCarthy P, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002, 29(1 Suppl 2):36-40.
77. Dupont B Introduction: current concepts in immunity to human cancer and therapeutic antitumor vaccines. Immunol Rev 2002, 188:5-8.
78. Aruffo A, Hollenbaugh D Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease. Curr Opin Immunol 2001, 13(6):683-686.
79. Biesecker G, Noble B, Andres GA, Koffler D Immunopathogenesis of Heymann's nephritis. Clin Immunol Immunopathol 1984, 33(3):333-338.
80. Cattran DC Effect of ciclosporin on active Heymann nephritis. Nephron 1988, 48(2):142-148.
81. Cavallo T Membranous nephropathy. Insights from Heymann nephritis. Am J Pathol 1994, 144(4):651-658.
82. Hasegawa Y, Kaneoka H, Tanaka T, Ogahara S, Matsumae T, Noda R, et al. Suppression of experimental membranous glomerulonephritis in rats by an anti-MHC class II antibody. Nephron 2001, 88(3):233-240.
83. Kerjaschki D, Neale TJ Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann nephritis). J Am Soc Nephrol 1996, 7(12):2518-2526.
84. Kerjaschki D Megalin/GP330 and pathogenetic concepts of membranous glomerulopathy (MGN). Kidney Blood Press Res 2000, 23(3-5):163-166.
85. Kupor LR, Lowance DC, McPhaul JJ Single and multiple drug therapy in autologous immune complex nephritis in rats. J Lab Clin Med 1976, 87(1):27-36.
86. Makker SP, Moorthy B In situ immune complex formation in isolated perfused kidney using homologous antibody. Lab Invest 1981, 44(1):1-5.
87. Makker SP, Makker DM A simple technique for detecting the antigen of Heymann nephritis in glomeruli by immunofluorescence. Clin Exp Immunol 1986, 64(3):615-622.
88. Matsukawa W, Hara S, Yoshida F, Suzuki N, Fukatsu A, Yuzawa Y, et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. J Lab Clin Med 1992, 119(2):116-123.
89. Nangaku M, Pippin J, Richardson CA, Schulze M, Young BA, Alpers CE, et al. Beneficial effects of systemic immunoglobulin in experimental membranous nephropathy. Kidney Int 1996, 50(6):2054-2062.
90. Penny MJ, Boyd RA, Hall BM Permanent CD8(+) T cell depletion prevents proteinuria in active Heymann nephritis. J Exp Med 1998, 188(10):1775-1784.
91. Schiller B, He C, Salant DJ, Lim A, Alexander JJ, Quigg RJ Inhibition of complement regulation is key to the pathogenesis of active Heymann nephritis. J Exp Med 1998, 188(7):1353-1358.
92. Singh AK, Kasinath BS Metabolic fate of monovalent and multivalent antibodies of Heymann nephritis following formation of surface immune complexes on glomerular epithelial cells. Clin Exp Immunol 1993, 94(3):403-411.
93. Spicer ST, Ha H, Boyd RA, He XY, Carter N, Tran G, et al. Il-4 therapy prevents the development of proteinuria in active Heymann nephritis by inhibition of Tc1 cells. J Immunol 2001, 167(7):3725-3733.
94. Yokoyama H, Goshima S, Wada T, Takaeda M, Furuichi K, Kobayashi K, et al. The short-and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa Study Group for Renal Diseases and Hypertension. Nephrol Dial Transplant 1999, 14(10):2379-2386.
95. Barabas AZ, Cole CD, Barabas AD, Barabas AN, Lafreniere R Effect of rat kidney fraction 3 (rKF3) antigen and specific IgM antibody against rKF3 on the progression of slowly progressive Heymann nephritis. Pathol Int 2006, 56(9):516-529.
96. Barabas AZ, Cole CD, Barabas AD, Cowan JM, Yoon CS, Waisman DM, et al. Presence of immunoglobulin M antibodies around the glomerular capillaries and in the mesangium of normal and passive Heymann nephritis rats. Int J Exp Pathol 2004, 85(4):201-212.
97. Pinckard RN, Weir DM Antibodies against the mitochondrial fraction of liver after toxic liver damage in rats. Clin Exp Immunol 1966, 1(1):33-43.
98. Manson JJ, Mauri C, Ehrenstein MR Natural serum IgM maintains immunological homeostasis and prevents autoimmunity. Springer Semin Immunopathol 2005, 26(4):425-432.
99. Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 2005, 35(1):252-260.
100. Barabas AZ, Cole CD, Barabas AD, Lafreniere R Pathogenic and nonpathogenic autoimmune events-the good and/or the bad?. Autoantibodies research progress 2008, 9-18. Nova Science Publishers, Inc., New York. Q. Dubois (Ed.).
101. Munshi CB, Fryxell KB, Lee HC, Branton WD Large-scale production of human CD38 in yeast by fermentation. Methods Enzymol 1997, 280:318-330.